Pharmacotherapy of amphetamine‐type stimulant dependence: An update
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Issues.: Methamphetamine‐ or amphetamine‐type stimulants are the second most frequently used illicit drug worldwide, second only to cannabis. Behavioural treatments are efficacious, but their impact is limited underscoring the need for other treatment options, notably, pharmacotherapy. Approach.: A review of randomised controlled trials of pharmacotherapies for methamphetamine‐ or amphetamine‐type stimulants was performed using PubMed and G oogle Scholar databases. Evidence for efficacy of medications is reported. Key Findings.: Clinical trials have yielded no broadly effective pharmacotherapy. Promising signals have been observed for methylphenidate, naltrexone, bupropion and mirtazapine in subgroups of patients in reducing stimulant use (e.g. patients with less severe dependence at baseline and men who have sex with men), though none has produced an unambiguous, replicable signal of efficacy. Implications.: Problems in Phase II trials, including high dropout rates, missing data and a lack of agreement on outcomes, complicate efforts to find a broadly effective pharmacotherapy for amphetamine‐type stimulant disorders. Efforts to address these problems include calls for better validation of pharmacological target exposure, receptor binding and functional modulation. As well, there is a need for agreement in using findings from preclinical and early phases of the medication development process for selecting better pharmacotherapy candidates. Conclusion.: After over 20 years of efforts worldwide to develop a broadly effective medication for dependence on methamphetamine‐ or amphetamine‐type stimulants, no candidate has emerged. This highlights the need for new compounds, consistent and stringent research methods, better integration between preclinical and clinical stages of medication development, and improved collaboration between government, industry and researchers. [Brensilver M, Heinzerling KG, Shoptaw S. Pharmacotherapy of amphetamine‐type stimulant dependence: An update. Drug Alcohol Rev 2013;32:449–460]
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566 · cited 1×
“The failure rates for central nervous system disorders appear even higher than for drugs being developed for other indications [89].”
BackgroundMolecular genetics of attention-deficit/hyperactivity disorder
Faraone, S. V., Perlis, R. H., Doyle, A. E., Smoller, J. W., Goralnick, J. J., Holmgren, M. A., & Sklar, P. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.11.024 · Cited by 2,357
Believe it or not: how much can we rely on published data on potential drug targets?
Prinz, F., Schlange, T., & Asadullah, K. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3439-c1 · Cited by 1,888 · cited 1×
“Some researchers have highlighted the need for better validation of pharmacological target exposure, receptor binding and functional modulation [91], whereas others underscore problems even earlier in drug development, namely target identification [92,93].”
BackgroundMorgan, P., Van Der Graaf, P. H., Arrowsmith, J., Feltner, D. E., Drummond, K. S., Wegner, C. D., & Street, S. D. A. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2011.12.020 · Cited by 692
A Comparison of Levomethadyl Acetate, Buprenorphine, and Methadone for Opioid Dependence
Johnson, R. E., Chutuape, M. A., Strain, E. C., Walsh, S. L., Stitzer, M. L., & Bigelow, G. E. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011023431802 · Cited by 623
Arrowsmith, J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3439 · Cited by 622
Varenicline Is a Partial Agonist at α4β2 and a Full Agonist at α7 Neuronal Nicotinic Receptors
Mihalak, K. B., Carroll, F. I., & Luetje, C. W. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.025130 · Cited by 558
Molecular Genetics of Attention Deficit Hyperactivity Disorder
Faraone, S. V., & Mick, E. (2010) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2009.12.004 · Cited by 411 · cited 1×
“Several single nucleotide polymorphisms (SNPs) have been linked to dopaminergic signalling [81], a clear target for pharmacological approaches to methamphetamine dependence.”
BackgroundNicotine Medications for Smoking Cessation
Henningfield, J. E. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511023331807 · Cited by 352 · cited 1×
“Nicotine replacement therapies are effective agonist approaches to treating nicotine dependence [24] and methadone and buprenorphine are effective agonist approaches for opioid dependence [25,26].”
BackgroundPre-morbid characteristics and co-morbidity of methamphetamine users with and without psychosis
CHEN, C.-K., LIN, S.-K., SHAM, P. C., BALL, D., LOH, E.-W., HSIAO, C.-C., CHIANG, Y.-L., REE, S.-C., LEE, C.-H., & MURRAY, R. M. (2003) · Psychological Medicine · doi:10.1017/s0033291703008353 · Cited by 295
Dwoskin, L. P., Rauhut, A. S., King‐Pospisil, K. A., & Bardo, M. T. (2006) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2006.00178.x · Cited by 259 · cited 1×
“Bupropion is a non-selective inhibitor of the dopamine and norepinephrine transporters and also acts as an antagonist at nicotinic acetylcholine receptors [53].”
BackgroundBupropion for the treatment of methamphetamine dependence
Elkashef, A. M., Rawson, R. A., Anderson, A. L., Li, S.-H., Holmes, T., Smith, E. V., Chiang, N., Kahn, R., Vocci, F., Ling, W., et al. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301481 · Cited by 234 · cited 2×
“[55] suggesting that among light users, bupropion may be efficacious”
BackgroundContingency Management for the Treatment of Methamphetamine Use Disorders
Roll, J. M., Petry, N. M., Stitzer, M. L., Brecht, M. L., Peirce, J. M., McCann, M. J., Blaine, J., MacDonald, M., DiMaria, J., Lucero, L., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.11.1993 · Cited by 196
Naltrexone for the Treatment of Amphetamine Dependence: A Randomized, Placebo-Controlled Trial
Jayaram-Lindström, N., Hammarberg, A., Beck, O., & Franck, J. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08020304 · Cited by 185 · cited 1×
“Following an encouraging open-label trial of naltrexone for amphetamine dependence [27], 80 treatment-seeking amphetaminedependent Swedish adults were randomised to placebo or 50 mg of naltrexone [28].”
BackgroundMirtazapine to Reduce Methamphetamine Use: A Randomized Controlled Trial
Colfax, G. N. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.124 · Cited by 175 · cited 1×
“[68] reported outcomes of a trial of mirtazapine (15 mg twice daily) in 60 men who have sex with men showing men assigned to receive mirtazapine showed fewer methamphetamine-positive urine samples compared with those assigned to placebo.”
BackgroundA double‐blind, placebo‐controlled trial of modafinil (200 mg/day) for methamphetamine dependence
Shearer, J., Darke, S., Rodgers, C., Slade, T., Van Beek, I., Lewis, J., Brady, D., McKetin, R., Mattick, R. P., & Wodak, A. (2009) · Addiction · doi:10.1111/j.1360-0443.2008.02437.x · Cited by 159
Co-activation of VTA DA and GABA neurons mediates nicotine reinforcement
Tolu, S., Eddine, R., Marti, F., David, V, Graupner, M., Pons, S., Baudonnat, M., Husson, M., Besson, M., Reperant, C., et al. (2013) · Molecular Psychiatry · doi:10.1038/mp.2012.83 · Cited by 151
Wachtel, S. R., Ortengren, A., & Wit, H. D. (2002) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(02)00104-7 · Cited by 138
The epidemiology of methamphetamine use and harm in Australia
DEGENHARDT, L., ROXBURGH, A., BLACK, E., BRUNO, R., CAMPBELL, G., KINNER, S., & FETHERSTON, J. (2008) · Drug and Alcohol Review · doi:10.1080/09595230801950572 · Cited by 134
Heinzerling, K. G., Swanson, A.-N., Kim, S., Cederblom, L., Moe, A., Ling, W., & Shoptaw, S. (2010) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2009.11.023 · Cited by 105
Self-citationA placebo‐controlled trial of mirtazapine for the management of methamphetamine withdrawal
CRUICKSHANK, C. C., MONTEBELLO, M. E., DYER, K. R., QUIGLEY, A., BLASZCZYK, J., TOMKINS, S., & SHAND, D. (2008) · Drug and Alcohol Review · doi:10.1080/09595230801935672 · Cited by 74 · cited 1×
“[69] assessed mirtazapine in a randomised double-blind trial of 31 methamphetamine-dependent adults.”
BackgroundNejtek, V. A., Avila, M., Chen, L.-A., Zielinski, T., Djokovic, M., Podawlitz, A., Kaiser, K., Bae, S., & Rush, A. J. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0808 · Cited by 69
McElhiney, M. C., Rabkin, J. G., Rabkin, R., & Nunes, E. V. (2009) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990802342907 · Cited by 61 · cited 1×
“mg/day [47] in HIV-positive patients with methamphetamine abuse and at 400 mg/day in a small sample of methamphetamine-dependent adults [48] found few adverse effects and no indication that the medication was habit-forming or a diversion risk.”
BackgroundAn Open-Label Pilot Study of Risperidone in the Treatment of Methamphetamine Dependence
Meredith, C. W., Jaffe, C., Yanasak, E., Cherrier, M., & Saxon, A. J. (2007) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2007.10399875 · Cited by 37 · cited 1×
“mixed dopamine and serotonin antagonist risperidone in small samples of methamphetamine-dependent adults to show acceptability [30] and decreases in weekly methamphetamine use that correlated with plasma risperidone levels [31].”
Background
Cited by
Courtney, K. E., & Ray, L. A. (2014) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2014.08.003 · Cited by 498
Heinzerling, K. G., Swanson, A., Hall, T. M., Yi, Y., Wu, Y., & Shoptaw, S. J. (2014) · Addiction · doi:10.1111/add.12636 · Cited by 64
“Despite multiple clinical trials of potential medications, no medication has been approved for the treatment of methamphetamine dependence [1].”
BackgroundSelf-citationStuart, A. M., Baker, A. L., Denham, A. M. J., Lee, N. K., Hall, A., Oldmeadow, C., Dunlop, A., Bowman, J., & McCarter, K. (2020) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2019.09.005 · Cited by 49
Shoptaw, S., Li, M. J., Javanbakht, M., Ragsdale, A., Goodman-Meza, D., & Gorbach, P. M. (2022) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2022.109320 · Cited by 37
Self-citationHeinzerling, K. G., Briones, M., Thames, A. D., Hinkin, C. H., Zhu, T., Wu, Y. N., & Shoptaw, S. J. (2020) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-019-09883-w · Cited by 30
Self-citation
Metadata
- Authors
- Brensilver, M., Heinzerling, K. G., & Shoptaw, S.
- Venue
- Drug and Alcohol Review
- Publisher
- Wiley
- Published
- 2013-04-25
- Volume
- 32
- Issue
- 5
- Pages
- 449-460
- ISSN
- 0959-5236 (ISSN-L)
- 1465-3362
- OpenAlex
- W2155613326
- Cited by
- 124
- References
- 24
- FWCI
- 12.11
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.